Filter By “Clinical Trials”

post-image
Oncology Experts Panel: How Real-World Data Propels Innovation in R&D Commercialization, and Beyond

In this conversation moderated by Vera Mucaj, Head of Trials and Chief Scientist at Datavant, our panelists will share how they’re thinking about current trends and future needs in oncology and RWD:etc...

Read More
post-image
Seqster Spotlight: The Value of a Patient-Centric & Real-Time Approach to Real-World Data

Eliminating healthcare data silos is not only important for healthcare institutions but can also improve the patient experience and their health in real-time. To reduce friction,etc...

Read More
post-image
Optimizing Real-World Data for Synthetic & External Control Arms

In this panel discussion moderated by Datavant, and featuring experts from Ikaika Health, Verantos, and Kantar Health to answer critical questions such as:etc...

Read More
post-image
External Control Arms Overview & Case Study

Download this overview to learn how Datavant powers external control arms and why they are important, using an oncology case study as an example.

Read More
post-image
The Value of Real-World Data in Clinical Trials

In this webinar, you will learn: What are examples of successful applications of real-world data in clinical trials? And, what role has COVID-19 played in reshaping this?etc...

Read More
post-image
What an open data ecosystem can do for clinical development

In this webinar, we discussed recent progress in clinical development, particularly given the FDA’s push to incorporate real world data for protocol feasibility analysis, hybrid trial design, etc...

Read More
post-image
Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE

Faraz S. Ahmad, Iben M. Ricket, Bradley G. Hammill, Lisa Eskenazi, Holly R. Robertson, Lesley H. Curtis, Cecilia D. Dobi, Saket Girotra, Kevin Haynes, Jorge R. Kizer, Sunil Kripalani, Mathew T. Roe, Christianne L. Roumie, Russ Waitman, W. Schuyler Jones, and Mark G. Weiner
This study outlines the recruitment process for the ADAPTABLE study (Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness), a pragmatic, randomized, open-label clinical trial that tested the optimal dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events. Investigators identified 650,000 potential eligible patients and recruited them at community sites, linking together data from the 40 sites in the Patient-Centered Outcomes Research Network to understand eligibility. The study was ultimately able to successfully enroll 15,076 patients in a significantly lower-cost way than most trials.

LEARN MORE
post-image
Introducing Datavant for Clinical Trials

We are excited today to announce Datavant for Clinical Trials, a solution that makes it easy for sponsors, CROs, and regulators to confidently bridge traditional clinical trial data with real-world data. This morning, we announced a multi-year strategic partnership with Parexel to roll out this connectivity solution across all of…

Read More
post-image
Administrative Claims Data to Support Pragmatic Clinical Trial Outcome Ascertainment on Cardiovascular Health

Qinli Ma, Haechung Chung, Sonali Shambhu, Matthew Roe, Mark Cziraky, W. Schuyler Jones, and Kevin Haynes
This study examined a retrospective cohort as part of the ADAPTABLE trial (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness). The trial was designed to compare the efficacy of different doses of Aspirin for the prevention of atherosclerotic cardiovascular disease events. By linking claims data from Anthem with data from the Patient-Centered Outcomes Research Network (PCORnet), the investigators were able to follow participants and understand their health outcomes without direct follow-up or bringing them into a trial site.

LEARN MORE